Open AccessPlasma proteome profiling discovers novel proteins associated with non‐alcoholic fatty liver disease
Author(s) -
Niu Lili,
Geyer Philipp E,
Wewer Albrechtsen Nicolai J,
Gluud Lise L,
Santos Alberto,
Doll Sophia,
Treit Peter V,
Holst Jens J,
Knop Filip K,
Vilsbøll Tina,
Junker Anders,
Sachs Stephan,
Stemmer Kerstin,
Müller Timo D,
Tschöp Matthias H,
Hofmann Susanna M,
Mann Matthias
Publication year - 2019
Publication title -
molecular systems biology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 8.523
H-Index - 148
ISSN - 1744-4292
DOI - 10.15252/msb.20188793
Subject(s) - biology , fatty liver , proteome , alcoholic liver disease , profiling (computer programming) , disease , computational biology , proteomics , bioinformatics , genetics , gene , pathology , medicine , cirrhosis , computer science , operating system
Non‐alcoholic fatty liver disease ( NAFLD ) affects 25% of the population and can progress to cirrhosis with limited treatment options. As the liver secretes most of the blood plasma proteins, liver disease may affect the plasma proteome. Plasma proteome profiling of 48 patients with and without cirrhosis or NAFLD revealed six statistically significantly changing proteins ( ALDOB , APOM , LGALS 3 BP , PIGR , VTN , and AFM ), two of which are already linked to liver disease. Polymeric immunoglobulin receptor ( PIGR ) was significantly elevated in both cohorts by 170% in NAFLD and 298% in cirrhosis and was further validated in mouse models. Furthermore, a global correlation map of clinical and proteomic data strongly associated DPP 4, ANPEP , TGFBI , PIGR , and APOE with NAFLD and cirrhosis. The prominent diabetic drug target DPP 4 is an aminopeptidase like ANPEP , ENPEP , and LAP 3, all of which are up‐regulated in the human or mouse data. Furthermore, ANPEP and TGFBI have potential roles in extracellular matrix remodeling in fibrosis. Thus, plasma proteome profiling can identify potential biomarkers and drug targets in liver disease.